Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

[This corrects the article DOI: 10.3389/fimmu.2021.709861.].

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology 2022-01, Vol.12, p.815812-815812
Hauptverfasser: Moreira, Thais G, Matos, Kimble T F, De Paula, Giovana S, Santana, Thais M M, Da Mata, Raquel G, Pansera, Fernando C, Cortina, Andre S, Spinola, Marcelle G, Baecher-Allan, Clare M, Keppeke, Gerson D, Jacob, Jules, Palejwala, Vaseem, Chen, Karen, Izzy, Saef, Healey, Brian C, Rezende, Rafael M, Dedivitis, Rogerio A, Shailubhai, Kunwar, Weiner, Howard L
Format: Artikel
Sprache:eng
Schlagworte:
anti-CD3
COVID-19
foralumab
immune responses
Immunology
SARS-CoV-2
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[This corrects the article DOI: 10.3389/fimmu.2021.709861.].
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.815812